Good MorningEquity markets wavered on Wednesday following some stronger-than-expected inflation data and hawkish commentary from the FOMC. On the inflation front, the PPI index advanced at a 0.4% month-over-month pace to double the expectations and leave the YOY figure up 8.5% from last year and at record levels. In regard to the FOMC, the Fed released the minutes from the last meeting and reinforced the idea that interest rates will move higher and stay higher for the foreseeable future.
Today's big news will be the CPI index which is expected to cool a bit from last month. The takeaway from the PPI report, however, is that producer-level inflation is still running hot and underpinning gains in consumer-level inflation. In this scenario, the CPI may cool versus last month but it should be expected to remain high and/or accelerate over the next few months to half a year. Featured: 100% overnight gains? (Ad) 
|
Consumer Staples | |
Nothing is more supportive of stock price over the long term than institutional buying. Institutions represent trillions of dollars of investible money and can produce strong tailwinds (or headwinds) for the market. The institutional tide has shifted due to the impacts of rising inflation, rising ... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Consumer Staples | |
Pepsico (NASDAQ: PEP) has been lagging behind the broad market since the pandemic bottom but that may be about to change. The company’s performance may be tied to its high valuation, it trades near 24X earnings, but the valuation is well earned and the stock has many attractive qualities for... Read the Full Story |
|
Technology | |
Apple (NASDAQ: AAPL) is increasingly witnessing stock downgrades, and analysts are increasingly worried that as the company’s forecasts for production come down from their previous estimates, revenue could in much slower than previously expected. The average price target is still around $180... Read the Full Story |
|
From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
|
Consumer Discretionary | |
Institutional Investors have been caught by high levels of volatility in the first-half of the trading year, and many have had to quickly re-assess their trading strategies. Moving away from high-flying growth stocks, to a much more balanced portfolio after many equity funds faced downturns and s... Read the Full Story |
|
Communication Services | | A 7% move higher since the last week of September versus the 3% drop seen in the NASDAQ index should tell you a lot about the potential in Take-Two Interactive Software Inc. (NASDAQ: TTWO). It’s true that the video game maker has put in a tough year so far, with shares recently down 40% from J... Read the Full Story |
|
From Our Partners | | Matt Monaco started with a $2,000 trading account and no clear strategy. After two years of trial and error, he crossed $1 million in 2020.
Today his account sits at $3 million, generating roughly $100,000 a month using a repeatable system he calls The Income Blueprint.
He's revealing the exact five-step scan and three trading lanes behind it in a free live training. | | Reserve your seat and claim The Income Blueprint free |
|
Energy | |
Energy stocks aren’t done yet.
The market’s only winning sector (by a wide margin) in 2022 is showing signs of life again following a modest summer swoon.
Leading the charge are oil and gas producers big and small that are all but locks to finish the year as the S&P 500’s ... Read the Full Story |
|
Consumer Discretionary | |
If the first week of October was any indication, equity investors are in for a volatile fourth quarter.
Last week, the major U.S. indices sprinted out of the gates only to limp back to the starting line by Friday. Good news on the labor market front was perceived as bad news for U.S. stocks as st... Read the Full Story |
|
Healthcare | | Literally synonymous with COVID-19 vaccines, pharmaceutical giant Pfizer Inc. (NYSE: PFE) has delivered over 367 million vaccinations in the U.S. alone and over 1.4 billion does worldwide since the pandemic began. Moderna Inc. (NASDAQ: MRNA) comes in a distant second place with over 230 million vacc... Read the Full Story |
|
Energy | | Energy, the lone soldier, stands as the only sector with a year-to-date gain. Texas Pacific Land Corporation (NYSE: TPL) leads in price in an industry that offers an alternative way to access oil and gas performance.
Shares rose 11.49% the week ended October 7, outpacing the S&P 500 by a wide ... Read the Full Story |
|
Consumer Staples | |
Kraft Heinz (NASDAQ: KHC) has offered deep value and high yield to investors for many years and the outlook for investors' returns continues to improve over time. The stock trades at a low 14x earnings compared to 15.8x for the broad market S&P 500 and anywhere from 20x to 35x for the highest-... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. | | View Today's Stock Pick |
|
